InvestorsHub Logo
Followers 48
Posts 12044
Boards Moderated 0
Alias Born 09/12/2017

Re: BioInvestor4 post# 117930

Saturday, 09/19/2020 5:11:01 PM

Saturday, September 19, 2020 5:11:01 PM

Post# of 233118
Leronlimab is worthless. No CEO, clinical trial patient enrollment, DSMB, or anything else will change that fact.

CYDY had a fair shot at proving/meeting its primary endpoint and it failed.

Its over.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News